Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine.
The smallpox vaccine is widely considered the gold standard for human vaccines, yet the key antibody targets in humans remain unclear. We endeavored to identify a stereotypic, dominant, mature virion (MV) neutralizing antibody target in humans which could be used as a diagnostic serological marker of protective humoral immunity induced by the smallpox vaccine (vaccinia virus [VACV]). We have instead found that diversity is a defining characteristic of the human antibody response to the smallpox vaccine. We show that H3 is the most immunodominant VACV neutralizing antibody target, as determined by correlation analysis of immunoglobulin G (IgG) specificities to MV neutralizing antibody titers. It was determined that purified human anti-H3 IgG is sufficient for neutralization of VACV; however, depletion or blockade of anti-H3 antibodies revealed no significant reduction in neutralization activity, showing anti-H3 IgG is not required in vaccinated humans (or mice) for neutralization of MV. Comparable results were obtained for human (and mouse) anti-L1 IgG and even for anti-H3 and anti-L1 IgG in combination. In addition to H3 and L1, human antibody responses to D8, A27, D13, and A14 exhibited statistically significant correlations with virus neutralization. Altogether, these data indicate the smallpox vaccine succeeds in generating strong neutralizing antibody responses not by eliciting a stereotypic response to a single key antigen but instead by driving development of neutralizing antibodies to multiple viral proteins, resulting in a "safety net" of highly redundant neutralizing antibody responses, the specificities of which can vary from individual to individual. We propose that this is a fundamental attribute of the smallpox vaccine.
Benhnia
Mohammed Rafii-El-Idrissi
MR
La Jolla Institute for Allergy and Immunology, Division of Vaccine Discovery, 9420 Athena Circle, La Jolla, CA 92037, USA.
McCausland
Megan M
MM
Su
Hua-Poo
HP
Singh
Kavita
K
Hoffmann
Julia
J
Davies
D Huw
DH
Felgner
Philip L
PL
Head
Steven
S
Sette
Alessandro
A
Garboczi
David N
DN
Crotty
Shane
S
D000914:Antibodies, Viral / Q000097:blood*; D002352:Carrier Proteins / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D009500:Neutralization Tests; D012900:Smallpox Vaccine / Q000276:immunology*; D014616:Vaccinia virus / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000276:immunology; D014764:Viral Proteins / Q000276:immunology; D014771:Virion / Q000276:immunology
D000914:Antibodies, Viral; D002352:Carrier Proteins; D007074:Immunoglobulin G; C087715:L1R protein, Vaccinia virus; D012900:Smallpox Vaccine; D014759:Viral Envelope Proteins; D014764:Viral Proteins; C406065:envelope H3L protein, Vaccinia virus